接受化疗的睾丸癌患者发生早期心血管事件的风险增加。识别出这些事件高风险的睾丸癌患者有助于制定预防策略。这项研究验证了血管指纹工具来识别这些患者。我们对转移性睾丸癌患者进行了一项多中心前瞻性研究[国际生殖细胞癌症协作组（IGCCCG）良好或中等风险；腹膜后肿块<5 cm]。在符合条件的患者中，在开始顺铂化疗前评估血管指纹，其中包括五个危险因素，即吸烟、超重（体重指数>25 kg/m2）、高血压（血压>140/90 mmHg） ）、血脂异常（空腹胆固醇>5.1 mmol/l或低密度脂蛋白胆固醇>2.5 mmol/l）和糖尿病（空腹血糖≥7.0 mmol/l）。存在三个或更多危险因素被定义为高危血管指纹。以化疗开始后1年内发生心血管事件为主要终点进行时序检验。共纳入196例转移性睾丸癌患者； 15 名患者 (8%) 发生心血管事件：4 名患者 (2%) 发生动脉血栓事件，11 名患者 (6%) 发生静脉血栓事件。总体而言，可获得 189 个血管指纹评分。具有高风险血管指纹 (62/189) 的患者发生心血管事件的风险较高（风险比 3.27，95% 置信区间 1.16-9.18；对数秩：P = 0.017）。有或没有心血管事件的患者的组织学诊断、预后组、累积化疗剂量和腹膜后肿块大小没有差异。所有发生动脉事件的患者都具有高风险血管指纹，而发生静脉事件的患者只有 5/11。发生心血管事件的患者中超重更为普遍（87% 对比 59%；P = 0.037）。血管指纹是一种经过验证的工具，可用于识别发生早期心血管事件高风险的睾丸癌患者。该工具可用于制定抗凝治疗的预防策略。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Patients with testicular cancer treated with chemotherapy have an increased risk of developing early cardiovascular events. Identification of patients with testicular cancer at a high risk of these events enables the development of preventative strategies. This study validates the vascular fingerprint tool to identify these patients.We carried out a multicenter prospective study in patients with metastatic testicular cancer [International Germ Cell Cancer Collaborative Group (IGCCCG) good or intermediate risk; retroperitoneal mass <5 cm]. In eligible patients, the vascular fingerprint was assessed before the start of cisplatin-based chemotherapy, which consists of five risk factors, namely, smoking, overweight (body mass index >25 kg/m2), hypertension (blood pressure >140/90 mmHg), dyslipidemia (fasting cholesterol >5.1 mmol/l or low-density lipoprotein-cholesterol >2.5 mmol/l), and diabetes mellitus (fasting glucose ≥7.0 mmol/l). The presence of three or more risk factors was defined as high-risk vascular fingerprints. A log-rank test was carried out with a cardiovascular event within 1 year after the start of chemotherapy as the primary endpoint.A total of 196 patients with metastatic testicular cancer were included; 15 patients (8%) developed a cardiovascular event: 4 (2%) arterial events and 11 (6%) venous thrombotic events. Overall, 189 vascular fingerprint scores were available. Patients with a high-risk vascular fingerprint (62/189) had a higher risk of developing a cardiovascular event (hazard ratio 3.27, 95% confidence interval 1.16-9.18; log-rank: P = 0.017). Histological diagnosis, prognosis group, cumulative chemotherapy dose, and retroperitoneal mass size did not differ between patients with or without a cardiovascular event. All patients with an arterial event had a high-risk vascular fingerprint compared with 5/11 patients with a venous event. Overweight was more prevalent in patients with cardiovascular events (87% versus 59%; P = 0.037).The vascular fingerprint is a validated tool to identify patients with testicular cancer at a high risk of developing early cardiovascular events. This tool can be used to develop preventative strategies with anticoagulant treatment.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.